Meeting
2016 ASCO Annual Meeting
TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.
Authors
David H. Ilson
Memorial Sloan Kettering Cancer Center, New York, NY
David H. Ilson , Josep Tabernero , Kohei Shitara , Robert Winkler , Ali Nasermoaddeli , Cliff Ding , Toshihiko Doi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02500043
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS4141)
DOI
10.1200/JCO.2016.34.15_suppl.TPS4141
Abstract #
TPS4141
Poster Bd #
128a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).
First Author: Maria Alsina
Poster
2016 Gastrointestinal Cancers Symposium
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase 3 RECOURSE trial.
First Author: Robert J. Mayer
Poster
2013 Gastrointestinal Cancers Symposium
REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.
First Author: Charles Fuchs
Poster
2023 ASCO Gastrointestinal Cancers Symposium
INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
First Author: Nick Pavlakis